Ovarian Cancer Clinical Trial
Official title:
A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel
Verified date | June 2011 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
RATIONALE: Drugs used in chemotherapy, such as carboplatin, gemcitabine, and paclitaxel,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy after
surgery may kill any tumor cells that remain after surgery. It is not yet known which
treatment regimen may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well giving one of two chemotherapy
regimens containing carboplatin, gemcitabine, and paclitaxel works in treating patients
undergoing surgery for newly diagnosed primary stage IIIC or stage IV ovarian cancer,
fallopian tube cancer, or primary peritoneal cancer.
Status | Active, not recruiting |
Enrollment | 88 |
Est. completion date | |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
DISEASE CHARACTERISTICS: - Clinically, radiologically, and histologically confirmed diagnosis of 1 of the following: - Primary epithelial ovarian cancer - Primary peritoneal carcinoma - Ovarian carcinosarcoma - Fallopian tube carcinoma - Newly diagnosed, stage IIIC/IV disease with or without ascites - None of the following histologies allowed: - Mucinous - Classic clear cell - Micropapillary or microacinar borderline tumors with or without invasive implants - Unsuitable for primary debulking surgery, as defined by the following: - Laparoscopic or other minor surgical-staging procedures - Supplementary clinical and radiological assessments - Presenting with factors affecting suitability for successful complete resection and necessarily prompting laparoscopic assessment, including any of the following: - CT scan or MRI evidence of peritoneal carcinomatosis, extensive mesenteric infiltration, diaphragmatic involvement, extensive retroperitoneal involvement, and cytologically verified malignant pleural effusion and/or ascites - Clinical evidence of ascites with radiological evidence of multisite disease - Clinical evidence of pelvic infiltration and radiological evidence of multisite disease - FIGO stage IV disease, including cervical/supraclavicular lymphadenopathy, intrahepatic parenchymal metastases, or cytologically confirmed malignant pleural effusion - No known brain metastases PATIENT CHARACTERISTICS: - ECOG performance status 0-3 - Life expectancy = 3 months - WBC > 3.0/mm³ - Platelet count = 100,000/mm³ - ANC = 1,500/mm³ - AST and ALT < 2.5 times upper limit of normal (ULN) - Alkaline phosphatase < 2.5 times ULN - Bilirubin < 1.5 times ULN - Estimated glomerular filtration rate = 30 mL/min - No diabetics, hypertensive smokers, or other patients with pre-existing occult neuropathic deficits - No poorly controlled, potentially serious medical conditions, including any of the following: - Cerebrovascular events within the past 12 months - Severe chronic respiratory conditions requiring prior hospitalization - Active infections - Poorly controlled seizures - Morbid psychiatric conditions likely to render treatment compliance with the protocol difficult - No other malignancy treated with chemotherapy or radiotherapy except nonmelanoma skin cancer or carcinoma in situ of the cervix - Prior malignancies disease-free for > 5 years not treated with chemotherapy allowed - No other reasons likely to cause inability to comply with treatment schedule and follow-up - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: - See Disease Characteristics |
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Birmingham Heartlands Hospital | Birmingham | England |
United Kingdom | Good Hope Hospital | Birmingham | England |
United Kingdom | Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust | Birmingham | England |
United Kingdom | New Cross Hospital | Wolverhampton | England |
Lead Sponsor | Collaborator |
---|---|
Warwick Medical School |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients completing 12 courses of chemotherapy | No | ||
Secondary | Toxicity | Yes | ||
Secondary | Quality of life as assessed by FACT-G, FACT-0, and FACT-T periodically | No | ||
Secondary | Objective response rate to the neoadjuvant phase of chemotherapy (i.e., first 6 courses) as assessed by CT scan, by laparoscopy, clinically, and by CA-125 level | No | ||
Secondary | Objective response rate following all 12 courses of treatment assessed clinically, by CT scan, and by CA-125 level | No | ||
Secondary | Progression-free survival, particularly at 34 weeks | No | ||
Secondary | Overall survival, particularly at 34 weeks | No | ||
Secondary | Rates of optimal and suboptimal interval debulking | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |